Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HT31-1

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

ARDS (acute Respiratory Distress Syndrome)Recruiting

ARDS (acute Respiratory Distress Syndrome)Phase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

ARDS (acute Respiratory Distress Syndrome)

NCT07449572

Clinical

Trials by Indication[1]

ARDS (Acute Respiratory Distress Syndrome)1 trial

A Phase 1/2A, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 (hCitH3-mAb) in Healthy Volunteers and in Patients With Mild-to-Moderate ARDS: Part A (Healthy Volunteers)

Recruiting·HHTIC, Inc·Phase 1·NCT07449572·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HT31-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HT31-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HT31-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HTIC, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHTIC, Inc

Related News